Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.


30 Sep 2019


Poster Display session 3


Tumour Site



Léa Dousset


Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255


L. Dousset1, L. Boussemart2, C. Robert3, S. Mansard4, C. Lebbe5, J. Merlio6, E. Routier7, A. Dupuy2, J. Rouanet8, M. Battistella9, D. Capellen6, M. Galibert10, C. Allayous11, A. Lespagnol10, G. Villechenoux12, E. Gerard1, I. Kerneuzet2, S. Roy7, B. Vergier13, M. Beylot-Barry14

Author affiliations

  • 1 Dermatology And Oncology, CHU Bordeaux - Hopital St. André, 33000 - Bordeaux/FR
  • 2 Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes/FR
  • 3 Dermatology Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 4 Dermatology And Oncologyy, CHU Estaing, 63003 - Clermont-Ferrand/FR
  • 5 Dermatology And Oncology, Hôpital Saint Louis, 75010 - Paris/FR
  • 6 Tumor Biology, CHU de Bordeaux-Hôpital Haut-Lévêque, 33604 - Pessac/FR
  • 7 Dermatology Unit, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 8 Dermatology Department, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand/FR
  • 9 Pathology, Hôpital Saint Louis, 75010 - Paris/FR
  • 10 Tumor Biology, Pontchaillou Hospital, CHU de Rennes, Rennes/FR
  • 11 Dermatology, Hôpital St. Louis, 75010 - Paris/FR
  • 12 Dermatology Unit, CHU Bordeaux - Hopital St. André, 33000 - Bordeaux/FR
  • 13 Pathology, CHU de Bordeaux-Hôpital Haut-Lévêque, 33604 - Pessac/FR
  • 14 Dermatology Departmentrtment, CHU Bordeaux - Hopital St. André, 33000 - Bordeaux/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5884


The era of immunotherapy changed considerably prognosis of melanoma. Nonetheless, only around 40% can get benefit from this treatment, with no biomarkers identified for the therapeutic choice. On the basis of emerging clinical evidence, increased Tumor Mutational Burden (TMB) may be associated with higher sensitivity to immunotherapeutic agents.


The aim of this study was to analyze in advanced melanoma the relationship between the mutation load and: i) the histologic characteristics, ii) locations according to sun exposure and iii) response to PD-1 inhibitors, in advanced melanoma patients, in a retrospective multicentric analysis by sequencing using FoundationOne®. TMB was characterized as the number of somatic protein-coding base substitution or alterations mutations per megabase (Mb). DNA was extracted from paraffin embedded sections of primary tumor or metastasis. TMB was considered low between 1 and 5 muts/Mb, intermediate between 6 and 19, high if > 20 muts/Mb.


In five centers in France, we included between October 2017 and March 2019 101 patients, aged from 16-year to 92-year-old, with metastatic melanomas. Results were available for 89 cases (12% DNA extraction failure). Acral (n = 6, 20%), mucosal (n = 5, 17%) and uveal melanoma (n = 4, 13%) had a lower TMB compared to sun-exposed melanomas. No melanoma of non-sun-exposed areas had high burden (n = 0); intermediate TMB was found in 21% (n = 8) and low TMB in 63% of cases (n = 19). Conversely, melanoma on chronic exposed areas (face and neck) had high TMB (5/7 cases; 71%). Complete and partial remission after 3 months of anti-PD-1 were more often observed in TMB high patients (n = 4;20%) whereas in low and intermediate mutational patients, progression was found in respectively 62% (n = 24) and 53% (n = 16).


TMB is affected by a variety of causes, including ultraviolet light in melanoma and smoking in lung cancer. Desmoplastic melanomas have been reported to have a high prevalence of somatic mutations whereas mucosal and acral have a 5-to 10-fold lower. Our study highlights the importance of TMB with higher response to PD-1 blockade. While it has to be confirmed, sun exposed areas or UV-signature may in be a valuable criterion in helping clinical decision-making.

Clinical trial identification

Editorial acknowledgement

Foundation One Medicine and Roche Laboratories.

Legal entity responsible for the study

French hospitals.


Has not received any funding.


C. Allayous: Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.